Molecular determinants of epistasis in HIV-1 protease: Elucidating the interdependence of L89V and L90M mutations in resistance

Protease inhibitors have the highest potency among antiviral therapies against HIV-1 infections, yet the virus can evolve resistance. Darunavir (DRV), currently the most potent FDA approved protease inhibitor, retains potency against single site mutations. However, complex combinations of mutations...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biochemistry
Main Authors: Henes, Mina, Kosovrasti, Klajdi, Lockbaum, Gordon J., Leidner, Florian, Nachum, Gily S., Nalivaika, Ellen A., Bolon, Daniel N.A., Yilmaz, Nese Kurt, Schiffer, Celia A., Whitfield, Troy W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6941756/
https://ncbi.nlm.nih.gov/pubmed/31386353
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.biochem.9b00446
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados